"Founded in 1938, St. Mary’s Medical Center is a 460-bed, acute care hospital that provides medical, surgical, obstetrical, pediatric, trauma and emergency services to a five-county area. What started as a small 50-bed facility founded by the Franciscan Sisters of Allegany, has grown into a dynamic institution, known for its innovation and award-winning programs, as well as a legacy of excellence that began more than three generations ago."

During the past decade, Saint Mary's Hospital conducted 58 clinical trials. In the 10-year time frame, 58 clinical trials started and 60 clinical trials were completed, i.e. on average, 103.4% percent of trials that started reached the finish line to date. In the past 5 years, 20 clinical trials started and 28 clinical trials were completed. i.e. 140% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Saint Mary's Hospital" #1 sponsor was "Children's Oncology Group" with 96 trials, followed by "National Cancer Institute (NCI)" with 42 trials sponsored, "Bristol-Myers Squibb" with 2 trials sponsored, "GlycoMimetics Incorporated" with 2 trials sponsored and "Bayer" with 2 trials sponsored. Other sponsors include 9 different institutions and companies that sponsored additional 19 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Saint Mary's Hospital" #1 collaborator was "National Cancer Institute (NCI)" with 96 trials as a collaborator, "Children's Oncology Group" with 4 trials as a collaborator, "Pfizer" with 2 trials as a collaborator, "ALN Implants Chirurgicaux" with 1 trials as a collaborator and "Argon Medical Devices" with 1 trials as a collaborator. Other collaborators include 21 different institutions and companies that were collaborators in the rest 31 trials.

According to Clinical.Site data, the most researched conditions in "Saint Mary's Hospital" are "Recurrent Neuroblastoma" (14 trials), "Recurrent Osteosarcoma" (12 trials), "Acute Lymphoblastic Leukemia" (10 trials), "Refractory Neuroblastoma" (10 trials) and "Leukemia" (9 trials). Many other conditions were trialed in "Saint Mary's Hospital" in a lesser frequency.

Most popular intervention types in "Saint Mary's Hospital" are "Drug" (120 trials), "Other" (82 trials), "Biological" (53 trials), "Procedure" (45 trials) and "Radiation" (45 trials). Other intervention types were less common.

The name of intervention was led by "Laboratory Biomarker Analysis" (54 trials), "Cyclophosphamide" (38 trials), "Vincristine Sulfate" (32 trials), "Etoposide" (26 trials) and "Doxorubicin Hydrochloride" (24 trials). Other intervention names were less common.

The vast majority of trials in "Saint Mary's Hospital" are 154 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "Saint Mary's Hospital". undefined are not yet recruiting, 30 are recruiting, 47 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 76 completed trials in Saint Mary's Hospital, 2 suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Saint Mary's Hospital, 6 "Phase 1" clinical trials were conducted, 55 "Phase 2" clinical trials and 67 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 3 trials that are defined as “Not Applicable".

Saint Mary's Hospital has several departments that took part in Clinical trials: "Kaplan Cancer Center at St. Mary's Medical Center" - 41 trials